Low molecular weight heparin offers several advantages concerning therapeutic efficacy and safety as compared to unfractionated heparin. Due to renal clearance of low molecular weight heparin problems with the use of low molecular weight heparins may occur in patients with renal failure. Current experience using low molecular weight heparin in patients with renal failure is based on single-dose pharmacokinetic studies, on retrospective analysis and on non-randomized prospective studies. Large randomized studies investigating the use of low molecular weight heparin (e. g. in acute coronary syndrome) have excluded patients with renal failure. Based on the findings mentioned above, treatment with low molecular weight heparin in patients with severe renal failure should follow only under special conditions. In moderate to severe renal failure monitoring anti-Xa activity may be useful to avoid bleeding complications. A definite cut-off level for a potential increase of bleeding complications with the use of

Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial

Full-sized and low-molecular weight heparins are widely used to treat a variety of clotting disorders. Although low-molecular weight heparins are safer and more convenient to use than full-size heparin, they are still animal-derived products that present a risk of contamination and supply chain interruptions and are limited with respect to standardization and reversibility of anticoagulation. A method developed by Xu et al. offers a potential alternative to animal-sourced heparins in the form of a chemical synthesis process that can be scaled up to produce heparin dodecasaccharides with reversible activity in adequate quantities for potential therapeutic use. ...

There are conflicting results as regards the impact of low molecular weight heparin (LMWH) on bleeding and mortality in elderly patients.. Aim: to compare in-hospital mortality in pts with AMI according to type of heparin used.. Methods: FAST-MI is a nationwide French registry carried out over a one-month period in the fall 2005, including consecutive pts with AMI admitted to CCUs =75 years and had received heparin therapy. Of those, 301 received unfractionated heparin (UFH) only, 398 LMWH only and 185 both UFH and LMWH. UFH only patients were slightly older (83 vs 82 years, p,0.01) and patients on LMWH only more often had NSTEMI: 65% vs 55% (UFH) and 50% (UFH+LMWH), p,0.01). Major bleeding was found in 6.3% (UFH), 2.3% (LMWH) and 2.7% (UFH+LMWH) (p,0.02). Blood transfusion was used in 10% (UFH), 4.8% (LMWH) and 4.3% (UFH+LMWH) (p,0.01). After x-variate adjustment, compared with UFH only, the need for transfusion was significantly lower (p,0.03) for LMWH OR=0.45 (95%CI: 0.25-0.85) and for ...

Data Synthesis:. Eleven of 37 studies met inclusion criteria for three major outcomes. Most studies used proper randomization procedures, but only one was double-blinded. Compared with unfractionated heparin, low-molecular-weight heparins reduced mortality rates over 3 to 6 months of patient follow-up (odds ratio, 0.71 [95% CI, 0.53 to 0.94]; P = 0.02). For major bleeding complications, the odds ratio favored low-molecular-weight heparins (0.57 [CI, 0.33 to 0.99]; P = 0.047), but the absolute risk reduction was small and not statistically significant (0.61% [CI, −0.04% to 1.26%]; P = 0.07). For preventing thromboembolic recurrences, low-molecular-weight heparins seemed as effective as unfractionated heparin (odds ratio, 0.85 [CI, 0.63 to 1.14]; P , 0.2). ...

Low molecular weight heparin in prevention of perioperative thrombosis.: Low molecular weight heparins seem to have a higher benefit to risk ratio than unfracti

The effectiveness of low-molecular weight heparin CY 216 in the prophylaxis of fatal pulmonary embolism in patients undergoing general surgery was assessed in a multicentre, double-blind, randomized, clinical trial against placebo. A total of 4,498 patients aged over 40 undergoing general surgery were enrolled in the 18 centres which took part in the trial. Patients received a single daily subcutaneous injection of 7,500 anti-Xa units I.C. of CY 216 or placebo two hours before surgery, 12 hours after the initial injection and then daily for at least seven days. A post-mortem examination had to be carried out in every patient who died. The two groups of patients were well-matched for age, sex, type of disease, site and duration of operation as well as for incidence of risk factors which could predispose to the development of thromboembolism. Twenty-six deaths were recorded and validated: eight (0.36%) in the CY 216 group and 18 (0.80%) in the placebo group (p less than 0.05). At the post-mortem ...

Parnaparin is an antithrombotic and belongs to the group of low molecular weight heparins. parnaparin at the US National Library of Medicine Medical Subject Headings (MeSH) Maugeri N, Di Fabio G, Barbanti M, de Gaetano G, Donati MB, Cerletti C (2007). Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood. Thromb. Haemost. 97 (6): 965-73. doi:10.1160/th06-12-0680. PMID 17549299 ...

Aguirre, J; Borgeat, A (2013). Drugs for thromboprophylaxis: unfractionated heparin, low molecular weight heparin warfarin, and fondaparinux. In: Llau, Juan. Thromboembolism in Orthopedic Surgery. London: Springer, 53-65. ...

Efficacy and safety of a low molecular weight heparin (Alfa LMWH) was compared with unfractionated heparin (UFH) in the prevention of post-operative venous thromboembolism after hip fractures. Forty-nine patients were randomized to treatment with Alf

TY - JOUR. T1 - Prospective trial of lower molecular weight heparin versus unfractionated heparin in moderately injured patients. AU - Cohn, Stephen M.. AU - Moller, B. A.. AU - Burns, G. A.. AU - Feinstein, A. J.. AU - Ginzburg, E.. AU - Hammers, L.. PY - 1998/10/1. Y1 - 1998/10/1. N2 - Purpose: To compare the safety and efficacy of low molecular weight heparin (LMH) with conventional unfractionated heparin (UH) in preventing deep venous thrombosis (DVT) in trauma patients with moderate injuries. Methods: We performed a prospective double-blind randomized trial at a level I trauma center. After informed consent, trauma patients meeting inclusion criteria (age,45 or requiring ,2 days bedrest) received LMH or UH twice daily. Patients were excluded if they had severe brain injuries or bleeding injuries not accessible to hemostatic control (eg: severe visceral contusions). Clinical examination and weekly venous duplex ultrasound evaluations were performed to identify DVT. Results: 104 moderately ...

TY - JOUR. T1 - Impairment of primary haemostasis by low molecular weight heparins in rats. AU - Borowska, A.. AU - Lauri, D.. AU - Maggi, A.. AU - Dejana, E.. AU - De Gaetano, G.. AU - Donati, M. B.. AU - Pangrazzi, J.. PY - 1988. Y1 - 1988. N2 - Different low molecular weight (LMW) heparins were tested on primary haemostasis in rats. Four preparations were studied; one was devoid of any effect on the bleeding time, while the other three prolonged the bleeding time to varying extents. As a consequence we studied the effect of these heparins on platelet aggregation. The fractions which prolonged the bleeding time, also inhibited the ex vivo and in vitro platelet aggregation, whereas the one devoid of any effect on the bleeding time did not affect platelet aggregation. Similar results were obtained using both platelet-rich plasma (PRP) and gel-filtered platelets. The in vitro response of platelets to aggregating agents may offer a parameter to detect the presence of bleeding factor(s) in some ...

Increasing number of people are being affected with Deep Vein Thrombosis (DVT) which will subsequently increase demand for LMWH. For instance, according to National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (CDC), February 2018; the precise number of people affected by DVT/PE is unknown, although as many as 900,000 people could be affected (1 to 2 per 1,000) each year in the U.S.. Furthermore, increasing engagement of government healthcare regulatory bodies in developing and delivering effective and cost-effective low molecular weight heparin molecule products in the market is expected to propel the growth of the market. For instance, in 2014, American Society of Health-System Pharmacists (ASHP) issued the policy for safe and effective use of heparin in neonatal patients thereby supporting the development and use of nationally standardized concentrations of heparin when used for maintenance and flush of peripheral and central venous lines ...

The purpose of this research is to gain insight into the way in which physicians adopt new practice techniques. In particular, we are interested in how medical innovations diffuse throughout social networks. We wish to examine the diffusion of Low Molecular Weight Heparin (LMWH) use for Deep Vein Thrombosis (DVT) throughout the social network of general internal medicine interns, residents, and attendings at the University of Chicago Hospital. In numerous clinical trials, LMWH has been demonstrated to be as effective as unfractionated heparin as a bridge to long-term anticoagulation therapy with Coumadin, with the added benefit of early discharge from the hospital with easy dosing, no need for monitoring, and home therapy. A DVT critical pathway was established at the U of C in 1998, and LMWH was used off-label for that purpose beginning in 1997. However, it is unclear how quickly the use of LMWH was adopted by the physicians on the general medicine services, or whether there exists a pattern ...

Restricted by the technology, the LMW heparin preparation market of China is dominated by foreign brands. In 2009, Chinese markets of LMW heparin sodium and LMW heparin calcium were dominated by France-based Sanofis Clexane and GSKs Fraxiparine, topping the market with the respective share of 54.5% and 59.0%. However, the LMW heparin preparation products made by domestic companies become increasingly competitive with the enhanced strength in R&D and technology. For instance, the sales of Hebei Changshan Biochemical Pharmaceutical, a company producing LMW heparin calcium injection, rose 72.6% YoY to RMB51.612 million in 2010 ...

Hiral Patel, PharmD Candidate 2015 Mercer University College of Pharmacy In patients with Non- ST-segment elevation myocardial infarction, fondaparinux was non-inferior to low molecular weight heparin in reducing ischemic outcomes. However, the use of fondaparinux reduced severe in-hospital bleeding events, which translated into both short- and long-term reduction in mortality.1 Title: Association between the use…

TY - JOUR. T1 - Safety assessment and pharmacodynamics of a novel ultra low molecular weight heparin (RO-14) in healthy volunteers - A first-time-in-human single ascending dose study. AU - Rico, Salvador. AU - Antonijoan, Rosa Maria. AU - Gich, Ignasi. AU - Borrell, Montserrat. AU - Fontcuberta, Jordi. AU - Monreal, Mayte. AU - Martinez-Gonzalez, Javier. AU - Barbanoj, Manel J.. PY - 2011/4/1. Y1 - 2011/4/1. N2 - Introduction: RO-14 is a novel ultra low molecular heparin. The purpose of this study was to evaluate the safety and pharmacodynamic profile of RO-14 in healthy males. Materials and methods: We conducted a two-stage, single-center, open-label, randomized study. Two cohorts of 6 volunteers were randomly assigned to 12 single, ascending subcutaneous doses (1750-19950 IU of anti-FXa activity) in an alternating crossover fashion. Safety was assessed by spontaneous/elicited adverse events, medical examination and laboratory tests. Anti-FXa activity and anti-FIIa activity were assessed ...

\for monoclonal antibodies bortezomib and low molecular weight heparins tender Tender Notices RFP Rfq compiled daily from all published Newspapers online web portals other sources of tender issuing authorities world wide

2017 Global Low Molecular Weight Heparin Industry Research Report Published by HongChun at researchbeam.com [Report Price $4000] 140 Pages

Low-molecular-weight heparin/protamine microparticles (LMW-H/P MPs) were produced as a carrier for heparin-binding growth factors (GFs) and for various adhesive cells. A mixture of low-molecular-weight heparin (MW: approximately 5000 Da, 6.4 mg/mL) and protamine (MW: approximately 3000 Da, 10 mg/mL) at a ratio of 7:3 (vol:vol) yields a dispersion of microparticles (0.5-3 µm in diameter). LMW-H/P MPs immobilize, control the release and protect the activity of GFs. LMW-H/P MPs can also bind to cell surfaces, causing these cells to interact with the LMW-H/P MPs, inducing cells/MPs-aggregate formation and substantially promoting cellular viability. Furthermore, LMW-H/P MPs can efficiently bind to tissue culture plates and retain the binding of important GFs, such as fibroblast growth factor (FGF)-2. The LMW-H/P MPs-coated matrix with various GFs or cytokines may provide novel biomaterials that can control cellular activity such as growth and differentiation. Thus, LMW-H/P MPs are an excellent carrier for

LMW heparin is now becoming a well established alternative to unfractionated heparin (UFH), particularly for the prophylaxis of deep vein thrombosis, where the convenience of a single injection a...

Dalteparin is a low molecular weight heparin. It is marketed as Fragmin by Pfizer Inc. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism. It is normally administered by self-injection. The CLOT study, published in 2003, showed that in patients with malignancy and acute venous thromboembolism, dalteparin was more effective than warfarin in reducing the risk of recurrent embolic events. Dalteparin is not superior to unfractionated heparin in preventing blood clots. Heparins are cleared by the kidneys, but studies have shown that dalteparin does not accumulate even if kidney function is reduced. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003). Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 349 (2): 146-53. doi:10.1056/NEJMoa025313. PMID 12853587. The ...

To evaluate whether initial (Low Molecular Weight) heparin followed by edoxaban only ([LMW] heparin/edoxaban) is non-inferior to initial (LMW) heparin overlapping with warfarin, followed by warfarin only ([LMW] heparin/warfarin) in the treatment of subjects with acute symptomatic VTE for the prevention of symptomatic recurrent VTE during the 12-month study ...

Restriction Description: A study site may not publish results of a study until after a coordinated multicenter publication has been submitted for publication or until one year after the study has ended, whichever occurs first. The study site will have the opportunity to publish results of the study, provided Daiichi Sankyo has had the opportunity to review and comment on the study sites proposed publication prior to being submitted for publication with the advice of patent council and need for subject protection ...

Effects of Reviparin, a Low-Molecular-Weight Heparin, on Mortality, Reinfarction, and Strokes in Patients With Acute Myocardial Infarction Presenting With ST-Segment Elevation Academic Article ...

Calibration Plasma LMW Heparin (82350063) is a lyophilised human plasma, prepared by addition of Heparin. Manufactured by Chromogenix.

0091]The methods described herein relate to combination therapies including a polyanion such as a polysaccharide, glycosaminoglycan (GAGs), heparin, low molecular weight heparin, chemically or enzymatically modified heparin or heparin sulfate, heparan sulfate mimetic (e.g., PI-88), chemically or enzymatically synthesized polysaccharide, e.g., K5 polysaccharide. In one embodiment, the polyanion, polysaccharide, GAG, heparin, low molecular weight heparin, chemically or enzymatically modified heparin or heparan sulfate, heparan sulfate mimetic or chemically or enzymatically synthesized polysaccharide lacks substantial anticoagulant activity, i.e., exhibits less than 50 IU/mg of anti-IIa activity and less than 50 IU/mg of anti-Xa activity. In one embodiment, the polyanion, polysaccharide, GAG, heparin, low molecular weight heparin, chemically or enzymatically modified heparin or heparan sulfate, heparan sulfate mimetic or chemically or enzymatically synthesized polysaccharide exhibits residual ...

Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logaparin). An experimental investigatin in healthy volunteers. ...

TY - JOUR. T1 - Inhibition of allergic airway responses by inhaled low-molecular-weight heparins. T2 - Molecular-weight dependence. AU - Martinez-Salas, José. AU - Mendelssohn, Richard. AU - Abraham, William M.. AU - Hsiao, Bernard. AU - Ahmed, Tahir. PY - 1998/1. Y1 - 1998/1. N2 - Inhaled heparin prevents antigent-induced bronchoconstriction and inhibits anti-immunoglobulin E-mediated mast cell degranulation. We hypothesized that the antiallergic action of heparin may be molecular weight dependent. Therefore, we studied the effects of three different low- molecular-weight fractions of heparin [medium-, low-, and ultralow-molecular- weight heparin (MMWH, LMWH, ULMWH, respectively)] on the antigen-induced acute bronchoconstrictor response (ABR) and airway hyperresponsiveness (AHR) in allergic sheep. Specific lung resistance was measured in 22 sheep before and after airway challenge with Ascaris suum antigen, without and after pretreatment with inhaled fractionated heparins at doses of 0.31-5.0 ...

Blood clotting, also known as coagulation, is the bodys first line of defense against bleeding. When we hurt ourselves, our clotting system forms a plug or seal to protect us from losing too much blood. Our bodies often break down the clot after weve healed - but sometimes, clots form inappropriately or fail to dissolve after an injury. A blood clot that forms and stays in a blood vessel is called a thrombus.. Other medical terms used to describe blood clots include:. Thrombosis: When a thrombus forms in a blood vessel. Embolus or Embolism: A clot that detaches and travels through blood vessels to another part of the body. There are two main types of thrombosis:. Arterial thrombosis refers to a blood clot that blocks an artery. Arteries carry blood away from the heart to other parts of the body. Arterial blood clots can block blood flow to the heart and brain, often resulting in a heart attack or stroke.. Venous thrombosis, also known as venous thromboembolism or VTE, refers to a blood ...

Cruickshank M, Cruickshank M, Cruickshank M, Cruickshank M. Subcutaneous low-molecular-weight heparin compared with standard heparin for deep-venous thrombosis had similar rates of recurrence and lower mortality and bleeding rates. ACP J Club. 1992;117:7. doi: 10.7326/ACPJC-1992-117-1-007. Download citation file:. ...

Introduction. The standard treatment for acute episode of deep vein thrombosis (DVT) included at least five days administration of unfractionated heparin followed by oral anticoagulants (OAs) in the subsequent months. In the early 2000s the use of low-molecular-weight heparins (LMWH) was recommended and validated as the equivalent for the standard therapy of acute episode of DVT. The aim of this study was to evaluate the patency of thrombotic venous segments and indirectly the function of valves after therapy with calcium nadroparine in the 10 days ambulatory treatment and three-month secondary prophylaxis of acute DVT.. Material and methods. The study group consisted of 50 patients (10 females and 40 males), aged 33 to 92 years (mean age 62.3 years) with first episode of acute, symptomatic deep vein thrombosis of the lower extremities, below the inguinal ligament, who were followed-up during their 10 days ambulatory treatment and three-month secondary prophylaxis with calcium nadroparine. Each ...

UCL Discovery is UCLs open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.

Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial ...

Patients with cancer are at increased risk for developing blood clots. There are several reasons for this: (a) Some cancers produce substances that activate the clotting system; (b) some chemotherapy drugs used to treat cancer can increase clotting risk; (c) some cancers, particularly breast cancer, is treated with hormonal therapy (Tamoxifen) that increase the risk for clots; (d) some patients have catheters in their veins (PICC, port, power-port, central venous lines) and these may narrow the blood vessel and, thus, increase the risk for clots. In addition, the usual risk factors - major surgery, hospitalization, immobility, overweight, hormones and inherited and acquired clotting disorders increase the risk further.. If you have cancer and are diagnosed with a blood clot, your initial treatment will likely be intravenous heparin or injection into the fat tissue of low molecular weight heparin (LMWH). The names of the low-molecular weight heparins are enoxaparin/Lovenox®, ...

Introduction: Low molecular weight heparins (LMWHs) are used worldwide for the treatment and prophylaxis of thromboembolic disorders. Routine laboratory tests are not required due to the predictable pharmacokinetics of LMWHs, with the exception of pregnant patients, children, patients with renal failure, morbid obesity, or advanced age. Anti-Factor Xa (anti-FXa) plasma levels are most often employed in the assessment and guidance of accurate dosing in these patient cohorts. Materials and methods: A LMWH calibration curve was generated using citrated human pooled plasma spiked with pharmacologically relevant concentrations (0-1 U/ml) of two low molecular weight heparins; enoxaparin and tinzaparin. Least squares analysis determined the best curve fit for this set of data which returned low sum of squares (SS) values for the log linear fit with an R2 value of 0.995. Patient sample concentrations for the fluorogenic anti- FXa assay were determined using the log linear regression equation and correlated with

Semantic Scholar extracted view of The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins. by Concetta Tiziana Ammollo et al.

TY - JOUR. T1 - Prevention of deep leg vein thrombosis. AU - Gallus, A. S.. PY - 1998/4/1. Y1 - 1998/4/1. N2 - Deep vein thrombosis remains a feared complication of injury, surgery and serious acute medical illness. Prevention is required whenever significant risk factors for thrombosis exist. Graded pressure elastic stockings and other physical methods for preventing venous stasis are suitable for patients who are at low to medium risk. Patients at high risk require standard heparin or a low molecular weight heparin. Either form of heparin will do for general surgery, but low molecular weight heparins are better in major joint replacement.. AB - Deep vein thrombosis remains a feared complication of injury, surgery and serious acute medical illness. Prevention is required whenever significant risk factors for thrombosis exist. Graded pressure elastic stockings and other physical methods for preventing venous stasis are suitable for patients who are at low to medium risk. Patients at high risk ...

TY - JOUR. T1 - Unfractionated Heparin for Hemodialysis. T2 - Still the Best Option. AU - Cronin, Robert E.. AU - Reilly, Robert F.. PY - 2010/9/1. Y1 - 2010/9/1. N2 - Unfractionated heparin (UFH) is the anticoagulant of choice for most maintenance hemodialysis units in the United States. Low molecular weight heparin (LMWH) is the norm in Western Europe, but is not approved for this indication in the United States. UFH is likely to remain the agent of choice in the United States because of its relative ease of use, safety, and low cost. Coating tubing and dialyzers with heparin is now possible, but systemic anticoagulation with heparin is usually still required. The additional cost of this innovation does not yet justify its use. Side effects of both UFH and LMWH include heparin-induced thrombocytopenia, hypertriglyceridemia, and hyperkalemia. It is uncertain whether osteoporosis is an important side effect, as vitamin D deficiency, secondary hyperparathyroidism, age, and debility are ...

The team determined that low-molecular-weight heparin did not reduce the frequency or severity of acute post-ERCP pancreatitis, compared to placebo. Furthermore, the 24-hour serum amylase values and pain scores did not differ significantly between the low-molecular-weight heparin group and the placebo group. There were 2 bleeding complications in the low-molecular-weight heparin group.. Dr Thomas Rabenstein and colleagues concluded, Prophylactic subcutaneous administration of low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. ...

This report studies sales (consumption) of Low-Molecular-Weight Heparin in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering

TY - JOUR. T1 - Low-Molecular Weight Metabolites from Polyphenols as Effectors for Attenuating Neuroinflammation. AU - Carregosa, Diogo. AU - Carecho, Rafael. AU - Figueira, Inês. AU - Santos, Cláudia N.. PY - 2019/2/19. Y1 - 2019/2/19. N2 - Age-associated pathophysiological changes such as neurodegenerative diseases are multifactorial conditions with increasing incidence and no existing cure. The possibility of altering the progression and development of these multifactorial diseases through diet is an attractive approach with increasing supporting data. Epidemiological and clinical studies have highlighted the health potential of diets rich in fruits and vegetables. Such food sources are rich in (poly)phenols, natural compounds increasingly associated with health benefits, having the potential to prevent or retard the development of various diseases. However, absorption and the blood concentration of (poly)phenols is very low when compared with their corresponding (poly)phenolic metabolites. ...

TY - JOUR. T1 - Aggregation kinetics of heated whey protein-stabilised emulsion: effect of low-molecular weight emulsifiers. AU - Euston, Stephen Robert. AU - Finnigan, S R. AU - Hirst, R L. PY - 2001. Y1 - 2001. M3 - Article. VL - 15. SP - 253. EP - 262. JO - Food Hydrocolloids. JF - Food Hydrocolloids. SN - 0268-005X. ER - ...

Devuyst, Olivier ; Jouret, François ; Dom, Geneviève ; Guggino, WB ; Cassiman, JJ. ; et. al. Low-molecular weight protein handling is largely preserved in cystic fibrosis (CF) kidney.36th Annual Meeting of the American-Society-of-Nephrology (SAN DIEGO (California), Nov 12-17, 2003). In: Journal of the American Society of Nephrology, Vol. 14, p. 319A-319A (2003 ...

Harvengt, C.. Drugs Recently Released in Belgium - Low-molecular Weight Heparin-ketanserin. In: Acta Clinica Belgica (Multilingual Edition), Vol. 43, no. 3, p. 242-245 (1988 ...

There have been a number of recent Datix reports where the wrong dose of LMWH (Enoxaparin, Tinzaparin) has been administered to patients

WHITE PHARMACEUTICALS - Exporter, Importer, Distributor, Supplier, Trading Company of Enoxaparin - Low Molecular Weight Heparin based in New Delhi, India

INTRODUCTION: Intravenous unfractionated heparin (UFH) is routinely used in patients after arterial embolectomy. Achieving and maintaining therapeutic levels requires a co-ordinated approach which may be difficult for busy junior doctors and laboratories. There is no current evidence regarding the use of subcutaneous low molecular weight heparin (LMWH) as an alternative. PATIENTS AND METHODS: The study retrospectively examined all patients who had undergone any form of embolectomy during 2006 and 2007 by review of their medical records, an electronic laboratory database, and the patients drug charts. RESULTS: Overall, 45 patients were studied. A total of 389 activated partial thromboplastin time (APTT) tests were performed of which 146 (37.6%) were in the therapeutic range (50-90 s), 40.4% were | 50 s and 22.1% were | 90 s. Five patients (11.1%) had further surgical procedures. Significant bleeding occurred in two patients. CONCLUSIONS: The results indicate that many patients are not appropriately

TY - JOUR. T1 - Colorimetric sensor for the determination of low-molecular-weight heparin. AU - Gavrilenko, Mikhail A.. AU - Gavrilenko, Nataliya A.. PY - 2017/7/1. Y1 - 2017/7/1. N2 - A colorimetric sensor was proposed for the visual and solid phase spectrophotometric detection of low-molecular-weight heparin in concentration ranges of 40-120 and 5-40 mg dm-3, respectively, with a detection limit of 2.0 mg dm-3 using a color destruction reaction of toluidine blue immobilized in an optically transparent polymethacrylate matrix.. AB - A colorimetric sensor was proposed for the visual and solid phase spectrophotometric detection of low-molecular-weight heparin in concentration ranges of 40-120 and 5-40 mg dm-3, respectively, with a detection limit of 2.0 mg dm-3 using a color destruction reaction of toluidine blue immobilized in an optically transparent polymethacrylate matrix.. UR - http://www.scopus.com/inward/record.url?scp=85026395908&partnerID=8YFLogxK. UR - ...

Antithrombotic prophylaxis in critically ill patients frequently fails. Venous thromboembolism is associated with adverse clinical outcomes, including a prolonged intensive care unit stay and death. A potential mechanism by which critically ill patients may be predisposed to antithrombotic failure is the inability to achieve prophylactic anticoagulant drug levels as a result of impaired absorption. For example, previous studies have shown that patients on inotropes have reduced serum levels of low molecular weight heparin, presumably on the basis of reduced absorption from the subcutaneous injection site. In the previous issue of the journal, Rommers and colleagues examined whether subcutaneous edema reduces absorption of a low molecular weight heparin; although small, and thus underpowered, the authors failed to find any relationship between the level of low molecular weight heparin and the presence of edema. These findings provide reassurance that subcutaneously administered medications may be used

TY - JOUR. T1 - Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. AU - Rodger, Marc A.. AU - Carrier, Marc. AU - Le Gal, Gregoire. AU - Martinelli, Ida. AU - Perna, Annalisa. AU - Rey, Evelyne. AU - De Vries, J. I P. AU - Gris, Jean Christophe. PY - 2014/2/6. Y1 - 2014/2/6. N2 - A 35-year-oldwomanwith recurrent severe placenta-mediated pregnancy complications in her 2 pregnancies asks: Will lowmolecular- weight heparin help prevent recurrent placenta-mediated pregnancy complications in my next pregnancy? We performed a meta-analysis of randomized controlled trials (RCTs) comparing low-molecular-weight heparin (LMWH) vs no LMWH for the prevention of recurrent placenta-mediated pregnancy complications. We identified six RCTs that included a total of 848 pregnant women with prior placenta-mediated pregnancy complications. The primary outcome was a composite of pre-eclampsia (PE), birth of a small-for-gestational-age (SGA) newborn (20 ...

Low-molecular-weight heparin (LMWH) is often recommended as a bridging therapy during temporary interruptions in warfarin treatment, despite lack of evidence. The aim of this study was to see whether we could find benefit from LMWH bridging. We studied all planned interruptions of warfarin within the Swedish anticoagulation register Auricula during 2006 to 2011. Low-molecular-weight heparin bridging was compared to nonbridging (control) after propensity score matching. Complications were identified in national clinical registers for 30 days following warfarin cessation, and defined as all-cause mortality, bleeding (intracranial, gastrointestinal, or other), or thrombosis (ischemic stroke or systemic embolism, venous thromboembolism, or myocardial infarction) that was fatal or required hospital care. Of the 14 556 identified warfarin interruptions, 12 659 with a known medical background had a mean age of 69 years, 61% were males, mean CHADS(2) (1 point for each of congestive heart failure, ...

Background- The combination of a single-bolus fibrinolytic and a low-molecular-weight heparin may facilitate prehospital reperfusion and further improve clinical outcome in patients with ST-elevation myocardial infarction.. Methods and Results- In the prehospital setting, 1639 patients with ST-elevation myocardial infarction were randomly assigned to treatment with tenecteplase and either (1) intravenous bolus of 30 mg enoxaparin (ENOX) followed by 1 mg/kg subcutaneously BID for a maximum of 7 days or (2) weight-adjusted unfractionated heparin (UFH) for 48 hours. The median treatment delay was 115 minutes after symptom onset (53% within 2 hours). ENOX tended to reduce the composite of 30-day mortality or in-hospital reinfarction, or in-hospital refractory ischemia to 14.2% versus 17.4% for UFH (P=0.080), although there was no difference for this composite end point plus in-hospital intracranial hemorrhage or major bleeding (18.3% versus 20.3%, P=0.30). Correspondingly, there were reductions in ...

TY - JOUR. T1 - Systematic synthesis of low-molecular weight fucoidan derivatives and their effect on cancer cells. AU - Kasai, Akihiro. AU - Arafuka, Shinsuke. AU - Koshiba, Nozomi. AU - Takahashi, Daisuke. AU - Toshima, Kazunobu. N1 - Publisher Copyright: © The Royal Society of Chemistry 2015. Copyright: Copyright 2015 Elsevier B.V., All rights reserved.. PY - 2015. Y1 - 2015. N2 - Low-molecular weight type I and II fucoidan derivatives with different sulfation patterns were designed and systematically synthesized from the corresponding common key intermediate and their anti-proliferative activities and apoptosis-inducing activities against human breast cancer (MCF-7) and human cervical epithelioid carcinoma (HeLa) cells were evaluated. Our results demonstrated that one of the type II fucoidan derivatives, 9, effectively reduced the number of viable MCF-7 and HeLa cells in a dose-dependent manner without causing cytotoxicity toward normal WI-38 cells, and that the anti-proliferative activity ...

Treatment Handbook Low-molecular-weight Heparins in Acute Coronary Syndromes and Venous Thromboembolism, D.A. Gorog, M. Marber, D. O'Shaughnessy, D. Perry books

TY - JOUR. T1 - High dose low-molecular-weight heparin (enoxaparin) for the treatment of recurrent thromboembolism in pregnancy. AU - Jha, R.. AU - Lindow, S. W.. AU - Masson, E. A.. AU - Atkin, Stephen. PY - 1997. Y1 - 1997. UR - http://www.scopus.com/inward/record.url?scp=0030941581&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0030941581&partnerID=8YFLogxK. M3 - Article. C2 - 15511813. AN - SCOPUS:0030941581. VL - 17. SP - 168. JO - Journal of Obstetrics and Gynaecology. JF - Journal of Obstetrics and Gynaecology. SN - 0144-3615. IS - 2. ER - ...

This study shows that the use of fixed dose, weight adjusted subcutaneous LMWH as an adjunct to rt-PA thrombolytic treatment for acute myocardial infarction induces stable and predictable aXa levels within the predefined target range. Patency rates at three to five days (80%) were comparable with the rt-PA arm (84%) in the GUSTO angiographic substudy.32 No major bleeding complications occurred. Hence this study shows that treatment with LMWH (nadroparine) is feasible and probably effective and safe as an adjunct to thrombolysis in patients with acute myocardial infarction. In clinical practice, treatment with LMWH does not require labourious laboratory monitoring and dose adjustments, which is a major advantage. Therefore, even if treatment with LMWH were no more effective than with unfractionated heparin, it would still have an important practical advantage. In addition, stable and predictable levels of anticoagulation are expected to result in fewer bleeding complications. As shown in the ...

Page contains details about N-octyl-N-quatenary chitosan cross-linked with low-molecular weight polyethylenimine/plasmid encoding enhanced green fluorescent protein complex nanoparticles . It has composition images, properties, Characterization methods, synthesis, applications and reference articles : nano.nature.com

Adequate coagulation function as defined by International Normalized Ratio (INR) ≤ 1.5, and a partial thromboplastin time (PTT) ≤ 5 seconds above the ULN (unless receiving anticoagulation therapy). Patients on full-dose anticoagulation must be on a stable dose (minimum duration 14 days) of oral anticoagulant or low molecular weight heparin (LMWH). Patients receiving warfarin/ phenprocoumon must be switched to low molecular weight heparin and have an INR ≤3.0 prior to first dose of protocol therapy. For heparin and LMWH there should be no active bleeding (that is, no bleeding within 14 days prior to first dose of protocol therapy) or pathological condition present that carries a high risk of bleeding (for example, tumor involving major vessels or known varices ...

The thrombosis of the portal vein represents an important milestone in the natural history of patients with cirrhosis, often increasing morbidity before and mortality after liver transplantation. Obtainment of recanalization through anticoagulation is therefore paramount, and in the present study, an analysis was performed regarding factors that may have an impact on efficacy of anticoagulation with low molecular weight heparin in cirrhotic patients with this complication. Anticoagulation with low molecular weight heparin was demonstrated to be a valid strategy for achieving portal vein recanalization, with a response rate of 65.2%, including complete recanalization in 24 of the 46 treated patients, after a mean of 4.5 months (±3.1 months) of anticoagulation. Whereas the hemostatic status of patients did not correlate with the response to anticoagulation, the interval between thrombus onset and start of therapy was the only predictive factor of therapeutic efficacy. Specifically, thrombus age ...

Results. Mean maximum plasma TFPI levels approached 150-230 ng/ml at the 0.8 h and up to 5 h posttinzaparin dose compared to basal TFPI levels of 35-90 ng/mL. Plasma TFPI levels were still about 2-fold above basal levels at 12 h and fell to basal levels at 16 h after tinzaparin dose. Basal plasma levels of NO, but not TFPI, were significantly lower ( ...

1. Marci CD, Prager D: A review of the clinical indications for the plasma heparin assay. Am J Clin Pathol 1993;99:546-550. 2. Houbouyan L, Boutiere B, Contant G, et al: Validation of analytical hemostasis systems: measurement of anti-Xa activity of low-molecular-weight-heparins. Clin Chem 1996;42:1223-1230. 3. Jeske W, Messmore HL Jr, Fareed J: Pharmacology of heparin and oral anticoagulants. In Thrombosis and Hemorrhage. Second edition. Edited by J Loscalzo, AI Schafer. Baltimore, MA, Williams and Wilkins, 1998, pp 1193-1204. 4. Monagle P, Michelson AD, Bovill E, Andrew M: Antithrombotic therapy in children. Chest 2001;119:344-370. 5. Fraser G, McKenna J: Monitoring low molecular weight heparins with antiXa activity: house of cards or firm foundation? Hospital Pharmacy 2003;38:202-211. 6. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE: Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. ...

A synthetic version of low molecular weight heparin is poised for clinical trials and development as a drug for patients with clotting disorders, and those undergoing procedures such as kidney dialysis, heart bypass surgery, stent implantation, and knee and hip replacement. Naturally derived low molecular weight heparin is extracted from pig intestines and the synthetic version offers several advantages: a synthesized version poses less risk for contamination in manufacturing, and, unlike its natural counterpart, it has been engineered to be safer for patients with poor kidney function and reversible in cases of complication.. Results of preclinical studies, which demonstrate the compounds safety and efficacy in animal models of deep vein thrombosis and sickle cell disease, appear in the journal Science Translational Medicine today.. This is at the cusp of clinical trials and commercial use. There is no question about the science; we have proven that this is a safer, more effective alternative ...

Unpublished data prepared by our department has shown that pregnant women display some resistance to the use of low molecular weight heparins. We would like to compare the use of enoxaparin and tinzaparin in pregnant women who have a previous history of venous thromboembolism, or who have inherited of acquired condition which predisposes them to venous thromboprophylactic doses as recommended by the respective manufacturers and monitoring the effects by using anti factor Xa assays and thromboelastography. ...

Home Dialysis Central was developed to raise the awareness and use of peritoneal dialysis (PD) and home hemodialysis. Developed by Medical Education Institute, Inc., Madison, WI.

Heparin Market report categorizes the global market by Product (Unfractionated Heparin, Low Molecular Weight Heparin & Ultra-low Molecular Weight Heparin), Source (Bovine and Porcine), Formulation (Oral & Parenteral) & Geography

Results In total, 25 patients were included. The majority were men (sex ratio (M/F)=1.27). Median age was 59 years (range 21-80). 19 cases of deep venous thrombosis, 4 of pulmonary embolisms and 3 of catheter associated thrombosis were diagnosed. As an initial treatment (first 5-10 days) of established VTE, 23 patients were treated with low molecular weight heparin (LMWH). Tinzaparin was prescribed in 22 cases. 2 patients received vitamin K antagonists (VKA). One of these 2 patients did not reach the target international normalised ratio (INR) range. Therefore, LMWH was substituted for VKA. For early maintenance and long term treatment, LMWH was used in 23 patients. The 2 other patients suffered from heparin induced thrombocytopenia during the initial treatment. As a result, LMWH was replaced by VKA. Duration of anticoagulation therapy varied from 2 to 18 months. 6 patients had complications of their VTE during treatment: 3 cases of VTE extension, 2 relapses and 1 case of pulmonary embolism. ...

Acute supportive treatment is reasonable in all patients and is aimed at restoring and maintaining normal circulating blood volume, perfusion, and oxygen and glucose delivery to the brain. These measures include:. Administer intravenous (IV) fluid at more than maintenance levels using isotonic fluids. Maintain airway, ventilation, and adequate oxygenation. Correct anemia. Monitor and maintain normal levels of blood glucose and sodium. Correct acid-base and electrolyte abnormalities. Elevate head of bed to 30 degrees. Consult hematologist about providing factor replacement or plasma products if there is consumptive coagulopathy or deficient levels of serum protein or fibrinolytic protein levels (protein C or S). AC therapy: systemic AC with heparin infusion or low-molecular weight heparin (LMWH) should be considered as urgent and first-line therapy for all children with acute CVT. The importance of starting therapy urgently with a minimum of delay should not be underestimated because clot ...

Discusses a study that evaluated the safety and efficacy of the thrombolytic drug tenecteplase plus either enoxaparin or unfractionated heparin in cases of ST-segment elevation myocardial infarction by doing a pooled analysis of data from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 and ASSENT-3 PLUS trials. Purpose of the ASSENT-3 trial; Reduction in rates of reinfarction and recurrent ischemia; Risk of intracranial hemorrhage among patients older than 75 years who received enoxaparin and tenecteplase ...

Preferred Name: Tinzaparin Sodium Definition: The sodium salt of a low molecular weight heparin (LMWH), obtained by controlled enzymatic depolymerization of heparin from porcine intestinal mucosa, with antithrombotic properties. Tinzaparin is a potent inhibitor of several activated coagulation factors, especially Factors Xa and IIa (thrombin); its primary activity is mediated through the plasma protease inhibitor antithrombin. In addition, this agent may inhibit angiogenesis through: 1) competitive binding of the heparin-binding sites on endothelial cells for the proangiogenic cytokines vascular endothelial growth factor (VEGF) and beta-fibroblast growth factor (beta-FGF) and 2) increasing the release of tissue factor pathway inhibitor (TFPI), a negative regulator of angiogenesis. NCI-GLOSS Definition: A drug that is used with another drug, warfarin, to treat blood clots that form deep in the veins and to prevent new blood clots from forming. It is a type of anticoagulant. Display Name: ...

This product thins the blood and prevents blockage of blood vessels. It belongs to the family of low-molecular weight heparins. It must be injected under the skin (subcutaneously) in the abdominal region, according to the technique you were shown. Be sure to choose a different injection site each time. WARNING: If you injure yourself, prolonged bleeding may occur. Report any excessive or unusual bleeding to your doctor. To reduce the risk of bleeding, do not consume alcohol, make any significant dietary changes, or take acetylsalicylic acid (ASA, e.g., Aspirin) unless prescribed by your doctor. ...

Cancer patients hospitalized for an acute medical illness are at increased risk of venous thromboembolism (VTE). Pharmacological thromboprophylaxis is considered standard practice for these patients and current guidelines recommend prophylactic doses of low-molecular-weight heparins (LMWHs), unfractionated heparin (UFH), or fondaparinux in the absence of bleeding or other contraindications [1-4]. These recommendations are extrapolated from large placebo-controlled randomized clinical trials (RCTs) of VTE thromboprophylaxis in broad mixed populations of medical inpatients, none involving exclusively cancer patients or presenting efficacy and safety data for this subgroup [5-8]. Because cancer inpatients represent a unique population with increased risk of VTE and major hemorrhage, validation of the efficacy and safety of thromboprophylaxis in this group is critical. ...

USP Anti-FXa & Anti-FIIa Assay for LMWH Buffer with PEG, pH 7.4, 1000 mL. Pre-weighed powder mix in sealed pouch (Store at 20-25°C). The contents of 1 pouch dissolved in 1000 mL of deionized water yields: |b|0.050 M Tris Buffer pH 7.4 @ 25°C, 0.150 M NaCI, 0.1% (w/v) PEG 6000.|/b| |p|For use as dilution buffer for standards, samples, AT, FXa, thrombin, and blank in USP and EP methods for Anti-FXa and Anti-FIIa activity assays for Low Molecular Weight Heparin (LMWH).|/p|

For any patient diagnosed with an acute DVT involving the iliac or femoral veins, the guidelines recommend starting a vitamin K antagonist such as Coumadin at the same time as the parenteral anticoagulation. The patient should continue parenteral anticoagulation for at least five days until the international normalized ratio, or INR, is at the goal range of 2 to 3 or higher for at least 24 hours (grade 1B).. Low-molecular-weight heparin or fondaparinux is recommended over intravenous unfractionated heparin (grade 2C for all comparisons). Once-daily administration is preferred over twice daily.. Initial treatment may take place at home under certain conditions (grade 1B) - if the patient has well-maintained living conditions, strong support from family or friends, phone access and the ability to return to the hospital quickly if needed.. Early mobility is preferred over bed rest (grade 2C). Compression stockings of at least 20 to 30 mmHg will help lower the risk of post-thrombotic ...

What are the options?. For stable outpatients starting anticoagulant therapy, the two most common options for oral therapy would be Warfarin (bridged with 5-7 days of Low Molecular Weight Heparin subcutaneous injections) or a Direct Oral Anticoagulant (Dabigatran, Rivaroxaban, or Apixaban). Most articles written about oral anticoagulant therapy for VTE over the past 5 years have some iteration of a table describing the properties of the DOACs (this is a good example here) 1.. A few other factors help determine whether your patient is a good candidate for a DOAC 2:. ...

General== *Type: [[Low molecular weight heparin]] *Dosage Forms: subcutaneous *Common Trade Names: Lovenox ==Adult Dosing== ===,u>Therapeutic,/u> anticoagulation (e.g. treating [[DVT]]/[[PE]], [[unstable angina]])=== *1mg/kg SC q12h {{Chemical prophylaxis of VTE}} ==Pediatric Dosing== Off-label *DVT prophylaxis: **,2 months: 0.75 mg/kg SC q12hr **≥2 months: 0.5 mg/kg SC q12h *Therapeutic anticoagulation: **,2 months: 1.5 mg/kg SC q12hr **≥2 months: 1 mg/kg SC q12hr ==Special Populations== *[[Drug Ratings in Pregnancy,Pregnancy Rating]]: B *Lactation: Unknown risk *Renal Dosing **Renal impairment (creatinine clearance ,30) ***Use 50% of usual dose or use UFH instead *Hepatic Dosing: not established *Obesity **Weight-based dosing safe up to 190kg (no data available thereafter) ==Indications== *[[DVT]] *[[PE]] *[[NSTEMI]] *[[STEMI]] ==Contraindications== *Allergy to class/drug ==Adverse Reactions== *Bleeding *Pruritus *Local skin reaction ==Pharmacology== *Half-life: 4.5h *Metabolism: ...

Anticoagulants are mainly categorized as herapins, warfarin, low molecular weight heparins (LMWHs), factor Xa inhibitors, and direct thrombin inhibitors (D

The National Institute of Health and Clinical Excellence (NICE) has published new guidance for the month of July 2012. This month there are two technology appraisals that impact upon primary care.. The adalimumab (Humira®) for the treatment of moderate to severe ulcerative colitis appraisal has been terminated and the treatment cannot be recommended. No evidence submission was made by the manufacturer or technology sponsor.. Rivaroxaban (Xarelto®) is recommended as an option for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. This treatment was evaluated against warfarin and low molecular weight heparins (LMWH). It is noted that in the short term this treatment is less expensive than other options. Over longer periods it becomes more expensive but the additional expense is justified by additional benefits in terms of less monitoring compared to warfarin and oral route of administration compared to LMWH.. Action: Clinicians should ...

Guidelines for cancer-associated venous thromboembolism (VTE) recommend both low molecular weight heparin (LMWH) and direct oral anticoagulants (DOAC).

Purpose: This retrospective review of a prospectively collected database was conducted to determine the efficacy of four years of an aggressive screening and prophylaxis protocol for venous thromboembolism (VTE) in a large trauma population. Methods: From Oct 2002 to Sept 2006, high-risk trauma patients received prophylaxis with both lower extremity (LE) mechanical compression and low molecular weight heparin after admission and were followed with weekly LE duplex ultrasound studies. Data were acquired from the trauma registry for patients with length of stay (LOS) |2 days and adjunctive chart review conducted in all patients with VTE. Results: Over 4 years, 2,939 patients were admitted to the Trauma service with LOS |2 days. Overall rates for deep venous thrombosis (DVT) and pulmonary embolus (PE) were 2.5% and 0.7%. High risk criteria of closed head injury, spinal cord injury, LE fractures, and pelvic fractures were present in 89% of VTEs. Duplex ultrasound was performed in 982 patients, 9% with DVTs.

in Physiological and Molecular Plant Pathology (2006), 67(3-5, SEP-OCT), 155-163. Plant pathogenesis-related proteins are toxic to invading pathogens. Among them, the Subfamily PR-1 represents low-molecular weight proteins of unknown biochemical function. Here, we describe the cloning ... [more ▼]. Plant pathogenesis-related proteins are toxic to invading pathogens. Among them, the Subfamily PR-1 represents low-molecular weight proteins of unknown biochemical function. Here, we describe the cloning and isolation of two PR-1 genes (PR-1b1 (GenBank accession no. SPH493450) and PR-1b2 (SPH493451)) that encode predicted basic proteins. We isolated them from Solanum phureja, a native Andean potato with horizontal resistance to late blight, caused by the oomycete Phytoplithora infestans. We demonstrate that the PR-1 genes belong to a small multigene family with an estimated copy number of 4-6 with one of them located oil chromosome IX as determined by genetic mapping. The expression of PR-1 genes ...

In this report, the global Unfractionated Heparin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Market Reports Center announces the addition of new study based research report on Unfractionated Heparin market…

Background: The purpose of this prospective study is to quantify the risk of lower limb deep venous thrombosis (DVT) in patients requiring temporary transvenous femoral pacing and to evaluate the use of different enoxaparin dosages (prophylactic or therapeutic) for thrombus prevention. Transvenous temporary cardiac pacemaker, with catheters frequently used along the femoral vein is useful to relieve difficult bradyarrythmias and some tachyarrythmias. Up to one-third of patients receiving transfemoral pacing develop asymptomatic DVT. At present, there are no recommendations for thrombus prophylaxis in these patients. Besides, the efficacy in this specific condition has not been studied.Methods: Sixty consecutive patients who underwent transvenous femoral pacing and had no contraindication to low molecular weight heparin (LMWH) therapy were divided into 3 groups each group consisted of 20 patients. Group I received prophylactic enoxaparin (1mg/kg/day; subcutaneously), group II received therapeutic

The unit of measurement for this measure is an inpatient episode of care. Each distinct hospitalization should be reported, regardless of whether the same patient is admitted for inpatient care more than once during the measurement period. In addition, the eMeasure logic intends to represent events within or surrounding a single occurrence of an inpatient hospitalization.. The definition of an ICU for the purpose of the measures noted above is that used by the CDC in the NHSN Patient Safety Project. An intensive care unit can be defined as a nursing care area that provides intensive observation, diagnosis, and therapeutic procedures for adults and/or children who are critically ill. An ICU excludes nursing areas that provide step-down, intermediate care or telemetry only and specialty care areas.. The construct of Unfractionated Heparin (route: Intravenous route) intends to capture continually infused heparin rather than heparin flushes or pushes.. ...

Conventional anticoagulants such as unfractionated heparin and warfarin have numerous limitations compared with low-molecular-weight heparin (LMWH). However, th...

A combined regiment of pneumatic compression, pressure stockings and low-dose heparin or low molecular weight heparin given prophylactically may reduce the incidence of venous thrombosis and this effect is better in early post SCI ...

Fingerprint Dive into the research topics of Treatment of proximal vein thrombosis with subcutaneous low-molecular- weight heparin vs intravenous heparin: An economic perspective. Together they form a unique fingerprint. ...